воскресенье, 10 апреля 2016 г.

Vertex Pharmaceuticals Incorporated (VRTX) Earns Outperform Rating from Leerink Swann

Vertex Pharmaceuticals Incorporated (VRTX) Earns Outperform Rating from Leerink Swann


A number of other research firms also recently weighed in on VRTX. Piper Jaffray reaffirmed an overweight rating and set a $180.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, January 5th.



from Biotech News